Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001877250 | SCV002128625 | uncertain significance | Singleton-Merten syndrome 1; Aicardi-Goutieres syndrome 7 | 2024-02-24 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 697 of the IFIH1 protein (p.Glu697Gly). This variant is present in population databases (rs775545790, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with IFIH1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1370603). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (Invitae) indicates that this missense variant is not expected to disrupt IFIH1 function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV004988831 | SCV005600410 | uncertain significance | Inborn genetic diseases | 2024-10-21 | criteria provided, single submitter | clinical testing | The c.2090A>G (p.E697G) alteration is located in exon 11 (coding exon 11) of the IFIH1 gene. This alteration results from a A to G substitution at nucleotide position 2090, causing the glutamic acid (E) at amino acid position 697 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |